NCT00472108View on ClinicalTrials.gov

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

April 30, 2002

Study Completion Date

April 30, 2002

Conditions
Basal Cell Carcinoma
Interventions
RADIATION

Photodynamic Therapy (PDT)

DRUG

Metvix cream

DRUG

Placebo Cream

Trial Locations (9)

14263

Department of Dermatology, Roswell Park Cancer Institue, Buffalo

55455

Department of Dermatology, University of Minnesota Hospital and Clinic, Minneapolis

55905

Department of Dermatology, Mayo Medical School, Mayo Clinic, Rochester

75230

Texas Dermatology Research Institute, Dallas

78759

DermResearch, Inc., Austin

87106

Academic Dermatology Associates, Albuquerque

97210

Northwest Cutaneous Research Specialists, Portland

230507

Virginia Clinical Research, Inc., Norfolk

90404-2115

Clinical Research Specialists Inc, Santa Monica

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT00472108 - Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter